A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system

• Authors: Leszek Śliwiński , Joanna Folwarczna , Barbara Nowińska , Urszula Cegieła , Maria Pytlik , Ilona Kaczmarczyk-Sedlak , Hanna Trzeciak , Henryk I Trzeciak
• Languages of publication: EN

Abstracts

EN

Genistein, a major phytoestrogen of soy, is considered a potential drug for prevention and treatment of postmenopausal osteoporosis. The aim of the present study was to compare the effects of genistein, estradiol and raloxifene on the skeletal system in vivo and in vitro. Genistein (5 mg/kg), estradiol (0.1 mg/kg) or raloxifene hydrochloride (5 mg/kg) were administered daily by a stomach tube to mature ovariectomized Wistar rats for 4 weeks. Bone mass, mineral and calcium content, macrometric parameters and mechanical properties were examined. Also the effects of genistein, estradiol and raloxifene (10-9-10-7 M) on the formation of osteoclasts from neonatal mouse bone marrow cells and the activity of osteoblasts isolated from neonatal mouse calvariae were compared. In vivo, estrogen deficiency resulted in the impairment of bone mineralization and bone mechanical properties. Raloxifene but not estradiol or genistein improved bone mineralization. Estradiol fully normalized the bone mechanical properties, whereas genistein augmented the deleterious effect of estrogen-deficiency on bone strength. In vitro, genistein, estradiol and raloxifene inhibited osteoclast formation from mouse bone marrow cells, decreasing the ratio of RANKL mRNA to osteoprotegerin mRNA expression in osteoblasts. Genistein, but not estradiol or raloxifene, decreased the ratio of alkaline phosphatase mRNA to ectonucleotide pyrophosphatase phosphodiesterase 1 mRNA expression in osteoblasts. This difference may explain the lack of genistein effect on bone mineralization observed in ovariectomized rats in the in vivo study. Concluding, our experiments demonstrated profound differences between the activities of genistein, estradiol and raloxifene towards the osseous tissue in experimental conditions.

Keywords

EN

bone mechanical properties; estradiol; osteoclasts; bone mineralization; osteoblasts; genistein; raloxifene

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2009
• Volume: 56
• Issue: 2
• Pages: 261-270

Dates

published

2009

received

2009-01-20

revised

2009-03-26

accepted

2009-04-24

(unknown)

2009-04-30

Contributors

author

Leszek Śliwiński

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Joanna Folwarczna

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Barbara Nowińska

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Urszula Cegieła

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Maria Pytlik

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Ilona Kaczmarczyk-Sedlak

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

author

Hanna Trzeciak

• Department of Prosthetic Dentistry, Medical University of Silesia, Bytom, Poland

author

Henryk I Trzeciak

• Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland

References

• Amano H, Yamada S, Felix R (1998) Colony-stimulating factor-1 stimulates the fusion process in osteoclasts. J Bone Miner Res 13: 846-853.
• Baker VL, Leitman D, Jaffe RB (2000) Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Surv 55 (Suppl 2): S21-S47.
• Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S (1998) Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112.
• Blair HC, Jordan SE, Peterson TG, Barnes S (1996) Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 61: 629-637.
• Cassidy A, Albertazzi P, Lise-Nielsen I, Hall W, Williamson G, Tetens I, Atkins S, Cross H, Manios Y, Wolk A, Steiner C, Branca F (2006) Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65: 76-92.
• Chen XW, Garner SC, Anderson JJ (2002) Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun 295: 417-422.
• Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116: 561-570.
• Erlandsson MC, Islander U, Moverare S, Ohlsson C, Carlsten H (2005) Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in mice. APMIS 113: 317-323.
• Evans GL, Bryant HU, Magee DE, Turner RT (1996) Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137: 4139-4144.
• Farahbakhsh NA (2003) Ectonucleotidases of the rabbit ciliary body nonpigmented epithelium. Invest Ophthalmol Vis Sci 44: 3952-3960.
• Folwarczna J, Janiec W, Śliwiński L (2004) Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 92: 940-946.
• Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E, Scambia G (2005) Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 12: 589-600.
• Gao YH, Yamaguchi M (1999) Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol 58: 767-772.
• Gao YH, Yamaguchi M (2000) Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med 5: 261-267.
• García Palacios V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE, Blair HC (2005) Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens. J Biol Chem 280: 13720-13727.
• Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164: 1199-1209.
• Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millán JL (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99: 9445-9449.
• Hofbauer LC, Kühne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4: 268-275.
• Kajiya H, Okabe K, Okamoto F, Tsuzuki T, Soeda H (2000) Protein tyrosine kinase inhibitors increase cytosolic calcium and inhibit actin organization as resorbing activity in rat osteoclasts. J Cell Physiol 183: 83-90.
• Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15: 175-191.
• Kryśkiewicz E, Lorenc RS (2006) RANKL/RANK/OPG system and its importance in bone physiology and pathophysiology. Terapia 3: 58-63.
• Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N (2002) p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143: 3105-3113.
• Liu BY, Guo J, Lanske B, Divieti P, Kronenberg HM, Bringhurst FR (1998) Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139: 1952-1964.
• Luben RA, Cohn DV (1976) Effects of parathormone and calcitonin on citrate and hyaluronate metabolism in cultured bone. Endocrinology 98: 413-419.
• Ma DF, Qin LQ, Wang PY, Katoh R (2008) Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr 62: 155-161.
• Mathey J, Mardon J, Fokialakis N, Puel C, Kati-Coulibaly S, Mitakou S, Bennetau-Pelissero C, Lamothe V, Davicco MJ, Lebecque P, Horcajada MN, Coxam V (2007) Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol. Osteoporos Int 18: 671-679.
• McCarty MF (2006) Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66: 1093-1114.
• McClain RM, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J (2006) Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 44: 56-80.
• Migliaccio S, Anderson JJ (2003) Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporos Int 14: 361-368.
• Morris C, Thorpe J, Ambrosio L, Santin M (2006) The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J Nutr 136: 1166-1170.
• Okumura N, Yoshikawa T, Iida J, Nonomura A, Takakura Y (2006) Bone formation-promoting effect of genistein on marrow mesenchymal cell culture. Biomed Mater Eng 16: 23-32.
• Om A-S, Shim J-Y (2007) Effect of daidzein, a soy isoflavone, on bone metabolism in Cd-treated ovariectomized rats. Acta Biochim Polon 54: 641-646.
• Pan W, Quarles LD, Song LH, Yu YH, Jiao C, Tang HB, Jiang CH, Deng HW, Li YJ, Zhou HH, Xiao ZS (2005) Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem 94: 307-316.
• Polkowski K, Mazurek AP (2000) Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 57: 135-155.
• Pytlik M, Folwarczna J, Janiec W (2004) Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int 75: 225-230.
• Reinwald S, Weaver CM (2006) Soy isoflavones and bone health: a double-edged sword? J Nat Prod 69: 450-459.
• Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325.
• Rickard DJ, Monroe DG, Ruesink TJ, Khosla S, Riggs BL, Spelsberg TC (2003) Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors α and β. J Cell Biochem 89: 633-646.
• Riggs BL (1991) Overview of osteoporosis. West J Med 154: 63-77.
• Setchell KDR, Lydeking-Olsen E (2003) Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 78 (3 Suppl): 593S-609S.
• Soucy NV, Parkinson HD, Sochaski MA, Borghoff SJ (2006) Kinetics of genistein and its conjugated metabolites in pregnant Sprague-Dawley rats following single and repeated genistein administration. Toxicol Sci 90: 230-240.
• Śliwiński L, Folwarczna J, Janiec W, Grynkiewicz G, Kuzyk K (2005) Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro. Pharmacol Rep 57: 352-359.
• Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30: 368-376.
• Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC (2002) Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J Cell Biochem 84: 725-735.
• Weaver CM, Cheong JM (2005) Soy isoflavones and bone health: the relationship is still unclear. J Nutr 135: 1243-1237.
• Williams JP, Jordan SE, Barnes S, Blair HC (1998) Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. Am J Clin Nutr 68 (6 Suppl): 1369S-1374S.
• Wronski TJ, Yen C-F (1991) The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Materials Suppl 1: 69-74.
• Yamagishi T, Otsuka E, Hagiwara H (2001) Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 142: 3632-3637.